Shanghai Tianhui Chemical & Pharmaceutical Co., Ltd.

1. Evaluate the safety and tolerability of single-dose administration in humans, and provide a theoretical basis for Phase II clinical trials and subsequent clinical applications. 2. Compare the pharmacokinetic characteristics of single intravenous infusion of this preparation and commercially available injections in humans, understand the absorption, distribution, and elimination of paclitaxel liposomes in the human body, and provide a theoretical basis for rational clinical drug use. 3. Objective remission rate, safety, and progression-free survival of single-drug treatment of recurrent and metastatic breast cancer.